ArticleHippokratia2007
Blood pressure control and cardiovascular risk reduction.
Article in Hippokratia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Group-delivered interventions for lowering blood pressure in hypertension: a systematic review and meta-analysis.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Pooled it
- Effects of qigong on systolic and diastolic blood pressure lowering: a systematic review with meta-analysis and trial sequential analysis.BMC complementary medicine and therapies · 2021Pooled it
- Impact of first-line antihypertensive drug class and intensity on NT-proBNP improvement and cardiovascular outcomes among hypertensive patients with pre-heart failure: findings from SPRINT trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Trial
- Acute effects of an oral nitric oxide supplement on blood pressure, endothelial function, and vascular compliance in hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2014Trial
- Disease burden, lifetime healthcare cost and long-term intervention impact projections among older adults in Singapore.Nature aging · 2025Article
- The pulsatile brain, pulse pressure, cognition, and antihypertensive treatments in older adults: a functional NIRS study.Journal of human hypertension · 2025Article
- Evaluation of Therapeutic Potential of Yoga Practice in Managing Hypertension Based on Cardiopulmonary Efficiency and Physical Fitness.Journal of pharmacy & bioallied sciences · 2024Article
- Burden of diseases due to high systolic blood pressure in the Middle East and North Africa region from 1990 to 2019.Scientific reports · 2024Article
- Therapeutic role of yoga in hypertension.World journal of methodology · 2024Review
- The Association Between Systemic Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Results from the U.S. National Health and Nutrition Examination Survey 1999-2018: A Cross-sectional Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- Evaluation of transitions from early hypertension to hypertensive chronic kidney disease, coronary artery disease, stroke and mortality: a Thai real-world data cohort.Frontiers in cardiovascular medicine · 2023Article
- Reasons behind high rate of non-compliance to scheduled office visits in hypertensive patients: results from the Egyptian registry of specialized hypertension clinics.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2022Article
- Long-term cardiovascular risk prediction in the emergency department: a mixed-methods study protocol.BMJ open · 2022Article
- A Cross-Sectional Study on Hypertension Medication Adherence in a High-Burden Region in Namibia: Exploring Hypertension Interventions and Validation of the Namibia Hill-Bone Compliance Scale.International journal of environmental research and public health · 2022Article
- Subjective sleep score is associated with central and peripheral blood pressure values in children aged 7-12 years.Journal of sleep research · 2022Article
- Risk factors for thrombotic events in Korean patients with systemic lupus erythematosus.Scientific reports · 2021Article
- Article
- Development and Psychometric Validation of the Hypertension Beliefs Assessment Tool Among Adult Population in Northwest Ethiopia.Patient preference and adherence · 2021Article
- Elucidation of a Causal Relationship Between Platelet Count and Hypertension: A Bi-Directional Mendelian Randomization Study.Frontiers in cardiovascular medicine · 2021Article
- Hypertension Surveillance in Rural Regions of Iran.Iranian journal of public health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ultimate goal of antihypertensive therapy is cardiovascular risk reduction. As lowering blood pressure per se reduces risk for myocardial infarction only by 20%-25%, it is obvious that a better protection is needed. An optimal strategy to reduce risk in hypertensives may include lifestyle modification, promotion of adherence to therapy, early and aggressive target levels achievement by appropriate drug choice. Clinical trial data suggest that RAAS blockers can reduce the risk at least partly independently of BP lowering. In addition, as hypertension is associated with a constellation of other risk factors, the global risk reduction is nowadays going to become the gold standard in therapy. The most common and important coexisting risk factor is hypercholesterolemia. This is not simply a co-existence but there is an independent and causal relationship between lipids and hypertension and there is a physiologic rationale and evidence for statins use especially in patients with complicated hypertension or in patients with more than two risk factors. So, whilst blood pressure lowering is undoubtedly beneficial, we have to focus on the global cardiovascular risk. We must go beyond blood pressure and the most effective way to go "beyond BP" is to add a statin.
Indexed as
Identifiers
19582204PMC2658793W2200936860What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.